Corporate GovernanceApr 26, 2026, 05:28 AM
SERA 2026 Annual Meeting on June 4; Highlights Clinical & Commercial Progress
AI Summary
Sera Prognostics, Inc. filed its definitive proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for June 4, 2026, virtually. The company highlighted significant progress in 2025 and early 2026, including the publication of the landmark PRIME Study demonstrating the PreTRM® test's effectiveness in reducing preterm births and newborn complications. Commercial engagement expanded across target states, and a successful $57.5 million equity financing extended the cash runway through 2028. The meeting agenda includes the election of three Class II directors and the ratification of Ernst & Young LLP as the independent auditor.
Key Highlights
- 2026 Annual Meeting of Stockholders to be held virtually on June 4, 2026, at 9:00 a.m. Mountain Time.
- Landmark PRIME Study published in January 2026, showing PreTRM® test reduced births before 32 and 35 weeks by 56% and 32%.
- PRIME Study also showed 20% fewer babies admitted to NICU and 20% reduction in neonatal morbidity.
- Expanded commercial engagement with 10 commercial and Medicaid payers across 13 states for PreTRM program adoption.
- Completed a successful follow-on equity financing in February 2025, generating approximately $57.5 million in gross proceeds.
- Financing extended cash runway through 2028.
- Shareholders to elect three Class II directors and ratify Ernst & Young LLP as independent auditor for 2026.
- Board determined six of eight directors are independent under Nasdaq listing standards.